Radotinib (IY-5511) is primarily used in the treatment of chronic myeloid leukemia (CML). It functions as a tyrosine kinase inhibitor, targeting the BCR-ABL fusion protein, which is a key driver of CML. By inhibiting this protein, Radotinib helps to control the proliferation of cancerous cells and slows disease progression. It is often considered for patients who are resistant or intolerant to other tyrosine kinase inhibitors, such as imatinib. Additionally, Radotinib has been studied for its potential in treating other cancers where tyrosine kinase activity plays a significant role. Its application in clinical settings provides an alternative therapeutic option for managing CML and improving patient outcomes.